The High-Stakes Battle Over The Future Of Mass Psychedelics
March 25, 2026
Legislators advance two different psychedelic therapy bills, will consider landmark programs for ibogaine and psilocybin
Legislators advance two different psychedelic therapy bills, will consider landmark programs for ibogaine and psilocybin
“I stabilized with cannabis and harm reduction and there was absolutely no space for that story in traditional recovery spaces”
Legislative proposals present differing pilot programs, sparking debate among experts and advocates on the future of psychedelics
Staff confusion, financial questions, and whistleblower allegations cloud the aftermath of the campaign to regulate psychedelics in the commonwealth On a mild night last fall,
The legislation is unique from other measures in consideration for its broad scope, including ibogaine and MDMA
A Q+A with Boston Psychedelic Society Founder Dr. Christina O’Flaherty
“I felt obligated to personally do something to help push decriminalization, and to tell people that psychedelics are nothing to be afraid of.”
An interview with Entheogen Melanin Collective Co-Founder Julian Fox
Latest psychedelics hearings featured new faces, old foes, and a historic endorsement for psychedelic decriminalization
Two former campaign staffers of the failed Yes on 4 ballot initiative in Massachusetts have filed complaints with the state Office of Campaign and Political Finance alleging violations of campaign finance law.